08 Mar 2022
Bristol-Myers Squibb: Financial & Price Forecasts, DCF Valuation, ESG & Other Risks (03/22)
Bristol-Myers Squibb had another strong quarter with strong results in their ongoing business, fueled by Eliquis and Opdivo, as well as continued demand growth for their new products. In the United States, the launch of Zeposia for ulcerative colitis is going well, and the company received European approval during the quarter. They are also expanding their cardiovascular portfolio and presented exciting data for Milvexian at AHA. They see it as the next-generation anti-thrombotic with a non-risk ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bristol-Myers Squibb: Financial & Price Forecasts, DCF Valuation, ESG & Other Risks (03/22)
Bristol-Myers Squibb Company (BMY:NYS) | 0 0 0.0%
- Published:
08 Mar 2022 -
Author:
Ishan Majumdar -
Pages:
16
Bristol-Myers Squibb had another strong quarter with strong results in their ongoing business, fueled by Eliquis and Opdivo, as well as continued demand growth for their new products. In the United States, the launch of Zeposia for ulcerative colitis is going well, and the company received European approval during the quarter. They are also expanding their cardiovascular portfolio and presented exciting data for Milvexian at AHA. They see it as the next-generation anti-thrombotic with a non-risk ....